| Name | AZ-23 |
| Description | AZ-23 is an inhibitor of ATP-competitive and Trk kinase A/B/C. For TrkA, TrkB, FGFR1, Flt3, Ret, MuSk, Lck, the IC50s values are 2 nM, 8 nM, 24 nM, 52 nM, 55 nM, 84 nM, 99 nM, respectively. |
| In vitro | AZ-23 selectively and potently inhibits Trk phosphorylation in cells, with an EC50 of 2 nM for Trk-mediated survival. It also inhibits Trk-dependent survival in MCF10ATrkA-Δ and TF-1 cell lines[1]. |
| In vivo | Following oral administration in a TrkA-driven allograft model, AZ-23 demonstrates effective in vivo inhibition of TrkA kinase and efficacy in mice. It also significantly inhibits tumor growth in a Trk-expressing xenograft model of neuroblastoma[1]. |
| Storage | Store at low temperature
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 125 mg/mL (319.02 mM), Sonication is recommended. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 4 mg/mL (10.21 mM), Sonication is recommended.
|
| Keywords | Tropomyosin related kinase receptor | Trkreceptor | TrkB | TrkA | Trk Receptor | Inhibitor | inhibit | AZ-23 |
| Inhibitors Related | Taletrectinib | Amitriptyline | Larotrectinib sulfate | N-Acetyl-5-hydroxytryptamine | Larotrectinib | SP600125 | 7,8-Dihydroxyflavone | Amitriptyline hydrochloride | Tepotinib | GW 441756 | ALE-0540 | NSI-189 Phosphate |